Rosetta Capital

Investment thesis

Life sciences investor specialising in direct secondary transactions, providing flexible liquidity solutions to existing investors and corporates in growth- and late-stage life science and medical device companies. 50+ venture investments over 20+ years with IPO/M&A exits mostly on NASDAQ and European exchanges.

Notable portfolio

Sector focus